The Pancreas Interception Center (PIC) for Early Detection, Prevention, and Novel Therapeutics

Launched by H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE · Jan 11, 2023

Keywords

ClinConnect Summary

The Pancreas Interception Center (PIC) is a clinical trial aimed at finding better ways to detect and prevent pancreatic cancer, specifically a type called pancreatic ductal adenocarcinoma (PDAC). The goal is to catch this disease early when it’s easier to treat, which may help save lives. The trial is currently looking for participants who are 18 years or older and are patients at the Moffitt Cancer Center. Eligible individuals may have a pancreatic cyst or genetic conditions that increase their risk of developing pancreatic cancer, or they may be undergoing evaluation for early-stage pancreatic cancer.

If you choose to participate, you can expect to be part of a program that focuses on monitoring and managing your risk for pancreatic cancer. This may involve various tests and assessments to help determine the best prevention or treatment strategies for you. It's important to know that the trial is open to people of all genders and is actively recruiting participants who meet the criteria, especially those with risk factors like a history of diabetes, pancreatitis, obesity, or tobacco use. Your involvement could contribute to advancements in how we understand and treat pancreatic cancer.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 18 years of age or older
• • Moffitt Cancer Center patients presenting with a pancreatic cyst, and/or inherited syndrome that predisposes them to pancreatic ductal adenocarcinoma (PDAC)
• • Moffitt Cancer Center patients undergoing evaluation for localized/early stage PDAC.
• • Moffitt Cancer Center patients with a combination of PDAC risk factors such as a history of chronic or new-onset diabetes, pancreatitis, obesity, tobacco exposure, toxin exposure and/or heavy alcohol consumption.